Back to today’s briefing

Story perspectives

Targeting Inflammation: New Hope for CKD Anemia Treatment

10/3/2025

48 7

Summary

Story summary

In chronic kidney disease (CKD), chronic inflammation contributes to anemia by directly affecting erythropoietin production.
Interleukin-6 is a key driver of anemia in juvenile CKD patients.
Therapies targeting hypoxia-inducible factors are being explored as potential CKD-related anemia treatments.
Adenine-induced CKD in rodent models reveals pathways to improve kidney injury outcomes and guide anemia treatment.

1 of 1

Story summary

In chronic kidney disease (CKD), chronic inflammation contributes to anemia by directly affecting erythropoietin production.
Interleukin-6 is a key driver of anemia in juvenile CKD patients.
Therapies targeting hypoxia-inducible factors are being explored as potential CKD-related anemia treatments.
Adenine-induced CKD in rodent models reveals pathways to improve kidney injury outcomes and guide anemia treatment.